Eosinophilic granulomatosis with polyangiitis: sequential use of mepolizumab following rituximab for inadequate asthma control despite vasculitis remission

This report reinforces the use of rituximab for induction and maintenance of remission in patients with eosinophilic granulomatosis with polyangiitis and predominant vasculitic manifestations, whereas mepolizumab demonstrated better control of the persistent eosinophilic manifestations, ensuing sustained remission and improved quality of life.PMID:38115776 | DOI:10.4081/reumatismo.2023.1588

Source: Reumatismo - December 20, 2023 Category: Rheumatology Authors: B Cremonezi Lammoglia L De Aguiar Trevise T Paslar Leal M Pereira Lopes Vieira Pinto G Hasselmann N Salles Rosa Neto Source Type: research